At -28.3x earnings, Insmed demands investors accept -0.88% yield versus 4.33% treasuries for unproven transformation.

At -28.3x earnings with a -0.88% yield versus 4.33% treasuries, this rare disease specialist embodies everything this framework warns against.

Does the price protect me from permanent loss of capital?

This framework sees no margin of safety whatsoever. The price demands belief in a transformation that current losses do not support. At 209.7% above even the most generous DCF estimate, any disappointment creates catastrophic downside.

Does the stock offer a meaningful premium over bonds to justify equity risk?

Applying this lens reveals the arithmetic impossibility. A -0.88% earnings yield against 4.33% risk-free returns is not an investment — it is speculation on biological transformation. Growth alone cannot justify this spread.

Has the company demonstrated consistent earnings over 7-10 years?

This framework requires demonstrated earnings, not promises. Despite improving margins and strong revenue growth, the company remains deeply unprofitable. Hope is not evidence.

Can the balance sheet survive a prolonged downturn?

The balance sheet provides temporary protection but not a fortress. At current burn rates, the $1.4B cash position depletes in under two years. This framework sees a countdown, not security.

Applying this framework to Insmed yields a clear conclusion: this is not an investment but a wager on biological transformation. With -28.3x earnings, a -5.21% yield spread to treasuries, and cash runway measured in quarters not years, the numbers offer no protection. Mr. Market's 209.7% premium to fundamental value suggests euphoria, not opportunity. Would Graham recognize this as investing or speculation?

This analysis applies Benjamin Graham's published investment framework to publicly available financial data. It is not authored by, endorsed by, or affiliated with Benjamin Graham. Educational purposes only. Not financial advice.